IP Library Granted Patent US 6,964,765
Granted Patent B2
US 6,964,765 · App. 10/934,717 · Granted Nov 15, 2005

Inhibitors of apoptosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,964,765
App. No.
10/934,717
Granted
Nov 15, 2005
Kind
B2
Abstract

The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis, for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.

Claims (6)

1. An isolated antibody specific for a human cellular inhibitor of apoptosis protein-1 (c-IAP1) said cIAP1 consisting of SEQ ID NO:2.

2. An isolated antibody specific for a human cellular inhibitor of apoptosis protein-2 (c-IAP2) said cIAP2 consisting of SEQ ID NO:4.

3. A method of making an antibody according to claim 1 , the method comprising the steps of eliciting the antibody in a rodent or rabbit, detecting human c-IAP1 (SEQ ID NO:2) binding specificity, and isolating the resultant antibody.

4. A method of using an antibody according to claim 2 , the method comprising the steps of eliciting the antibody in a rodent or rabbit, detecting human c-IAP2 (SEQ ID NO:4) binding specificity, and isolating the resultant antibody.

5. A method of using an antibody according to claim 1 , the method comprising the steps of combining the antibody and c-IAP1 (SEQ ID NO:2), and detecting specific binding of the antibody to the c-IAP1.

6. A method of using an antibody according to claim 2 , the method comprising the steps of combining the antibody and c-IAP2 (SEQ ID NO:4), and detecting specific binding of the antibody to the c-IAP2.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2005
From: AMGEN SF, LLC
To: AMGEN INC.
Reel/Frame 016871/0736 →
CHANGE OF NAME Recorded Jun 7, 2005
From: ARROW ACQUISITION, LLC
To: AMGEN SF, LLC
Reel/Frame 016309/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2004
From: ROTHE, MIKE; GODDEL, DAVID V.
To: TULARIK, INC.
Reel/Frame 015774/0137 →